Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms
Elevance Health ELV | 311.83 311.83 | +3.05% 0.00% Post |
Evolent Health Inc Class A EVH | 2.54 2.54 | +9.96% 0.00% Post |
Humana Inc. HUM | 197.15 197.10 | +7.94% -0.03% Post |
KKR & Co Inc Class A KKR | 90.75 90.75 | -0.33% 0.00% Post |
TPG Inc Class A TPG | 37.99 37.99 | +0.16% 0.00% Post |
Evolent Health Inc (NYSE:EVH) is reportedly up for sale.
What Happened: The Arlington, Virginia-based software provide initiated an auction process after receiving takeover inquiries from private equity firms and healthcare providers.
Among the potential suitors are private equity giants TPG Inc (NASDAQ:TPG), Clayton, Dubilier & Rice (CD&R), and KKR & Co. Inc. (NYSE:KKR). Notably, TPG was one of Evolent's early investors.
Reuters noted that health insurer Elevance Health Inc (NYSE:ELV) has also expressed interest and may join forces with a private equity partner to pursue a deal.
Founded in 2011, Evolent offers software solutions to help healthcare providers and insurers transition from fee-for-service to value-based care models. The company partners with prominent industry players like Humana Inc. (NYSE:HUM).
Why It Matters: Evolent has seen financial challenges despite a 38% revenue increase in its latest quarter. The company struggled with lower billing rates from payer customers, leading to results below market expectations.
Its history of attracting acquisition interest includes a 2021 Bloomberg report that Walgreens Boots Alliance, Inc. (NASDAQ:WBA) was considering a deal.
Activist investor Engaged Capital took a significant stake in Evolent in 2020 and pushed for changes to enhance shareholder value.
Price Action: EVH stock is up 0.62% at $32.30 during the premarket session at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
- AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support.